BC030336 Inhibitors
Chemical inhibitors of BC030336 operate through various mechanisms to block its activity within cellular signaling pathways. PD98059 and U0126 are both inhibitors of MEK, a kinase that phosphorylates and activates ERK. Since BC030336 operates downstream of the ERK pathway, these inhibitors prevent the phosphorylation and subsequent activation of BC030336 by halting the ERK signaling cascade. Similarly, LY294002 and Wortmannin target the PI3K/Akt pathway, with LY294002 being a potent inhibitor of PI3K, and Wortmannin acting as an irreversible inhibitor of the same kinase. The inhibition of PI3K leads to a decrease in Akt activity, which is necessary for the proper functioning of BC030336. Rapamycin, on the other hand, inhibits mTOR, another crucial component of the PI3K/Akt/mTOR pathway, and this inhibition results in a blockade of downstream signaling that would normally involve BC030336.
Further inhibitors like SP600125, SB203580, and ZM447439 disrupt other pathways linked to BC030336. SP600125 inhibits JNK, and by doing so, it blocks a pathway upstream of BC030336, preventing its activation. SB203580 specifically inhibits p38 MAPK, another pathway that BC030336 is a part of, and therefore, its inhibition directly impairs the functionality of BC030336. ZM447439 targets Aurora kinases, which are involved in cell cycle control, a process that BC030336 regulates. Thus, the inhibition of these kinases disrupts the cell cycle events that BC030336 is associated with. Additionally, Dasatinib and PP2 are broad-spectrum tyrosine kinase inhibitors. Dasatinib inhibits Bcr-Abl and Src family kinases, while PP2 is more specific to Src family kinases. Since BC030336 is associated with signaling pathways that involve these kinases, the use of these inhibitors prevents the activation of BC030336. Lastly, Lestaurtinib and Sorafenib target different kinases; Lestaurtinib inhibits JAK2, a kinase in pathways mediating BC030336 activity, and Sorafenib targets multiple receptor tyrosine kinases and Raf kinases, all of which are part of the complex signaling networks that BC030336 is involved in, hence their inhibition leads to the functional suppression of BC030336.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which is known to phosphorylate and activate ERK. By inhibiting MEK, PD98059 prevents the activation of ERK, which is a pathway BC030336 is involved in. Therefore, the inhibition of MEK by PD98059 leads to the functional inhibition of BC030336 due to the blockade of its downstream signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). Since PI3K is upstream of Akt signaling, and Akt is a pathway BC030336 is involved in, the inhibition of PI3K by LY294002 would lead to decreased Akt activity and subsequent inhibition of BC030336's function that is dependent on Akt signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathways. BC030336 operates downstream of JNK signaling. Thus, by inhibiting JNK, SP600125 functionally inhibits BC030336 by blocking the signaling cascade necessary for its activity. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB203580 is a selective inhibitor of p38 MAPK. The p38 MAPK signaling pathway is one of the pathways that BC030336 is a part of. Inhibition of p38 MAPK by SB203580 would result in functional inhibition of BC030336 due to the interruption of its associated signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another inhibitor of MEK, similar to PD98059, and it prevents the activation of ERK. Since BC030336 is involved in the ERK pathway, inhibition of MEK by U0126 will lead to the functional inhibition of BC030336 by halting the phosphorylation and activation of ERK that is required for BC030336's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a steroidal molecule that functions as a potent and irreversible inhibitor of PI3K. Given that BC030336 activity is contingent on PI3K/Akt signaling, inhibition of PI3K by wortmannin would impede the pathway and functionally inhibit BC030336. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is a well-known inhibitor of the mammalian target of rapamycin (mTOR), which is part of the PI3K/Akt/mTOR signaling pathway. Because BC030336 is active within this pathway, inhibition of mTOR by rapamycin would functionally inhibit BC030336 by blocking downstream signaling events. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Bcr-Abl and Src family kinases. Since BC030336 is part of signaling pathways that involve these kinases, dasatinib's inhibition of these kinases could inhibit BC030336 by preventing activation of the pathways it requires. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $270.00 $320.00 $600.00 | 3 | |
Lestaurtinib is a potent inhibitor of Janus kinases (JAK), particularly JAK2. BC030336's activity is mediated through pathways involving JAK2, and inhibition of JAK2 by lestaurtinib would lead to functional inhibition of BC030336. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. These kinases are involved in multiple signaling pathways, including those associated with BC030336. Thus, inhibition of Src kinases by PP2 would functionally inhibit BC030336 by disrupting necessary signaling events. | ||||||